The White House recently issued an executive order accelerating the use of psychedelics, such as psilocybin, MDMA, and ibogaine, in research and clinical trials. This order, however, does not change…
Read More
For an industry built on the promise of transformation, psychedelic medicine is starting to look a lot more like traditional pharma. The language has shifted. Words like “set and setting”…
Read More
Enveric Biosciences Inc. (NASDAQ:ENVB) on Tuesday highlighted preclinical findings for its lead candidate EB-003. It pointed to rapid reductions in PTSD-related fear responses, as recent federal policy signals growing support…
Read More
The psychedelic medicine sector has spent years building momentum on the back of compelling clinical narratives. But as 2026 unfolds, the conversation is evolving into something more technical, and arguably…
Read More
President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For…
Read More
A conversation with Joseph Tucker, Ph.D., CEO, Enveric Biosciences Non-hallucinogenic neuroplastogens are being developed as a potentially safer alternative to psychedelics, with a lower risk of hallucinations. Enveric Biosciences is…
Read More
In biotech, competitive lines are often drawn in the lab. Increasingly, they are drawn in patent court. This week, Enveric Biosciences announced that a Post Grant Review petition filed against…
Read More
Enveric Biosciences Inc. (NASDAQ:ENVB) on Wednesday said that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals Inc. against Enveric's issued U.S. Patent No. 12,138,276 (the '276 patent)…
Read More
In a development that could ripple across the fast evolving neuroplastogen sector, Enveric Biosciences announced that a Post Grant Review petition filed against one of its key U.S. patents has…
Read More
Enveric Biosciences reported new mechanistic data showing that its lead neuropsychiatric candidate EB-003 engages both Gq and β-arrestin signaling downstream of the 5-HT2A receptor, based on proprietary bioluminescence resonance energy…
Read More
